Literature DB >> 25814516

Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT).

Michael S Hofman1, Michael Michael1, Raghava Kashyap1, Rodney J Hicks1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25814516     DOI： 10.2967/jnumed.115.154500

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  6 in total

1.  Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging.

Authors:  Paolo Zanotti-Fregonara; Clément Morgat; Christophe Champion; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-10       Impact factor: 9.236

Review 2.  Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.

Authors:  Valentina Ambrosini; Lucia Zanoni; Angelina Filice; Giuseppe Lamberti; Giulia Argalia; Emilia Fortunati; Davide Campana; Annibale Versari; Stefano Fanti
Journal:  Cancers (Basel)       Date:  2022-02-19       Impact factor: 6.639

3.  High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.

Authors:  Grace Kong; Jason Callahan; Michael S Hofman; David A Pattison; Tim Akhurst; Michael Michael; Peter Eu; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-09-27       Impact factor: 9.236

4.  Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.

Authors:  Sonya Park; Ashwin Singh Parihar; Lisa Bodei; Thomas A Hope; Nadine Mallak; Corina Millo; Kalpna Prasad; Don Wilson; Katherine Zukotynski; Erik Mittra
Journal:  J Nucl Med       Date:  2021-07-22       Impact factor: 11.082

5.  The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.

Authors:  Elif Hindié
Journal:  Theranostics       Date:  2017-03-01       Impact factor: 11.556

6.  Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias.

Authors:  Ioannis Karfis; Gwennaëlle Marin; Hugo Levillain; Stylianos Drisis; Raoul Muteganya; Gabriela Critchi; Loubna Taraji-Schiltz; Carlos Artigas Guix; Leila Shaza; Meriem Elbachiri; Laura Mans; Godelieve Machiels; Alain Hendlisz; Patrick Flamen
Journal:  Oncotarget       Date:  2020-02-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.